Synagis (palivizumab) is a man-made antibody to respiratory syncytial virus (RSV) used to prevent serious lung disease caused by RSV in premature infants, and infants born with certain lung disorders or heart disease. Synagis will not treat a child who is already sick with RSV disease.The recommended dose of Synagis is 15 mg per kg of body weight given monthly by intramuscular injection.